Baricitinib

Drug Profile

Baricitinib

Alternative Names: INCB-028050; INCB-28050; LY-3009104; Olumiant

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Incyte Corporation
  • Class Acetonitriles; Antipsoriatics; Antirheumatics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Rheumatoid arthritis
  • Phase II Atopic dermatitis; Giant cell arteritis; Systemic lupus erythematosus
  • Phase Unknown Psoriatic arthritis
  • Discontinued Diabetic nephropathies; Psoriasis

Most Recent Events

  • 01 Aug 2017 Eli Lilly is still planning a phase III trial for Psoriatic arthritis in USA, Spain and Germany
  • 25 Jul 2017 Eli Lilly and Company announces delay in resubmission of NDA to the US FDA for Rheumatoid arthritis beyond 2017
  • 03 Jul 2017 Registered for Rheumatoid arthritis (Treatment-experienced) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top